News

Duke researchers tested a program that involves hair stylists in raising awareness, possible uptake of HIV preexposure prophylaxis (PrEP) among Black women, a group that is disproportionately affected by new HIV infections.

The FDA has removed the approval of Pepaxto in multiple myeloma. The agency approved Amtagvi, the first TIL therapy for a solid tumor, as well a new biweekly dosing of Tecvayli for multiple myeloma. The agency has set actions for several products, including a first-in-class lung cancer therapy, a bispecific antibody for advanced multiple myeloma, and another for Dupixent for COPD

In this month’s episode of Tuning In to the C-Suite, Briana Contreras, an editor of Managed Healthcare Executive, got to chatting with Sanjula Jain, Ph.D., chief research officer at Trilliant Health.

The information systems of Change Healthcare, a recently acquired subsidiary of UnitedHealth Group, were disconnected on Wednesday.

The results of this week’s poll about Medicaid work requirements.

A study suggests that a novel CAR T-cell therapy could be a curative treatment for some patients with chronic lymphocytic leukemia, with 25% of responders still in remission after 6 years.

The economy and healthcare costs are the issues voters want to hear about going into the 2024 presidential election, finds a survey by KFF.

The greatest savings are seen for 90-tablet prescriptions.

Research results reported in the journal Science today add to the evidence that “immunogenetics” likely influences people’s susceptibility to developing lung cancer, especially among smokers.

Because of expensive specialty drugs, pharmacy expenditures accounted for one-quarter of healthcare spending by public sector health plans, according to a new report by two public sector health plan groups.

This new initiative brings together provider groups, purchasers and end users committed to evidence-based, cost-effective, equitable digital health solutions.

Research and development funding increased in 2023 but clinical trial starts fell by 15%, partly because of fewer COVID-19-related trials, according to IQVIA's worldwide report on research and development in the biopharmaceutical industry.

New insight could change the way physicians treat disorders like insomnia.

Official recommendations from the American Gastroenterological Association.

There was a record-breaking total of 725 breaches in 2023.

Heart failure, renal failure, atrial fibrillation and death are among the events that can happen years after a myocardial infarction.

It’s likely droughts will become more common due to climate change.

Majority of leaders think AI will help them expand the capabilities of healthcare.

The Health and Human Services department could wind up overpaying (or possibly underpaying) for the drugs for which it is negotiating a “maximum fair price” for Medicare under the Inflation Reduction Act, argue experts at the USC Schaeffer Center for Health Policy and Economics. A fuller picture of rebates and net prices could help that from happening, they say.

Do you favor Medicaid work requirements?

Researchers have identified an association between cataract surgery and a lower risk of cognitive decline and dementia.

For operational efficiency, value-based initiatives need a scalable digital infrastructure that can handle multiple reimbursement models, including fee for service.

The FDA approves Eohilia for eosinophilic esophagitis and Onivyde for metastatic pancreatic cancer but extends review of gene therapy for rare immune disorder. The agency also set goal dates for three products: full approval for Elevidys, Augtyro for solid tumors with NTRK gene fusions and seladelpar as for rare liver disease.

The results of this week’s poll about Super Bowl LVIII commercials.

This makes CSU treatment the sixth approved use globally.

The rule comes as health insurers have increasingly been criticized for onerous and time-consuming prior authorization procedures that physicians say unfairly delay or deny the medical treatment that their patients need.

The cheapest medication on the list is hydrochlorothiazide at $4.55.